Published on: 2026-04-14
As of April 14, 2026, the Arxis IPO has launched but has not yet been priced. The deal is expected to price during this week, with Nasdaq trading widely scheduled for April 16 under the ticker ARXS.
The offering is for 37.7 million shares at $25 to $28, implying gross proceeds of roughly $943 million to $1.06 billion before expenses.
At the range, Arxis implies an equity valuation of about $10.0 billion to $11.2 billion, based on roughly 401.6 million shares outstanding after the offering.
The business mix is attractive: 47% defense and space, 23% commercial aerospace, and 30% industrial technology, with about 90% of revenue tied to proprietary products.
Currently, Arxis IPO sits at the intersection of rising demand for defense and space hardware and renewed investor appetite for high-margin aerospace component businesses.
That combination can support aggressive pricing, but only if the market accepts Arxis as a durable compounder rather than a private-equity roll-up coming public near the top of the quality cycle.
Arxis filed its S-1 on March 24, added terms in an amended filing on April 8, and stated an expected IPO range of $25.00 to $28.00 per share for 37,735,849 Class A shares. The company says the shares will list on Nasdaq under ARXS.
Market calendars and IPO trackers are pointing to Thursday, April 16, 2026, as the expected first trading day, though that remains contingent on final pricing.
That schedule indicates that Arxis is testing a live market window, not a hypothetical one. The deal is expected to price during the week of April 13, which means investors are making a near-term judgment on risk appetite for sponsor-backed industrial issuers while defense-linked names remain in favor.
Arxis is selling a scaled components platform with real operating breadth. The company serves over 5,000 customers and operates on more than 600 platforms. No individual customer or platform contributed more than 7% of 2025's revenue. That diversification matters in aerospace and defense, where supplier concentration can quickly turn into program risk.
The stronger part of the story is product economics. In 2025, approximately 90% of revenue was generated from proprietary or uniquely designed products. Arxis states that many of these components are integrated into systems early on and continue to be used throughout their long platform lifespans and in aftermarket replacement cycles.
Some platforms remain in service for more than 40 years, which helps explain why investors may be willing to pay a higher multiple than they would for a standard build-to-print manufacturer.
The growth profile also looks better once the acquisition noise is separated from the core business. Historical 2025 revenue was $1.591 billion, up 114.1% year over year, but only 8.9% of that was organic. That is still respectable, and it was led mainly by defense and space plus commercial aerospace pricing and volume, but it confirms that Arxis remains heavily shaped by acquisitions.
| Metric | 2025 |
|---|---|
| Revenue | $1.591 billion |
| Net Income | $46.0 million |
| Adjusted EBITDA | $571.3 million |
| Adjusted EBITDA Margin | 35.9% |
| Operating Cash Flow | $251.2 million |
| Free Cash Flow | $208.8 million |
| Total Debt, Pre-IPO | $2.66 billion |
| Total Debt, Post-IPO Pro Forma | $1.92 billion |
*Source data from the April 8, 2026, S-1/A filing.
The numbers are strong enough to support investor interest. A 35.9% adjusted EBITDA margin is well above what the market expects from ordinary industrial distributors or commodity parts makers.
Fitch's peer analysis positions Arxis alongside aerospace component companies like HEICO, Signia, and TransDigm. It emphasizes that Arxis's profit margins are more comparable to those of higher-quality specialty component firms than to those of lower-margin industrial competitors.
At the midpoint, Arxis would carry an equity value of roughly $10.64 billion. Using pro forma adjusted debt and cash, enterprise value lands around $12.1 billion, or about 21x adjusted EBITDA. At the top end, EV rises to about $12.7 billion, or roughly 22.3x adjusted EBITDA.
That is the real test. Investors are being asked whether Arxis should be valued as a premium franchise, despite lacking a public-market track record and still operating under sponsor control.
Additionally, its balance sheet remains leveraged even after the IPO, with a post-offering net leverage of approximately 2.6x and gross leverage still above 3.3x, based on rough calculations. Post-offering net leverage is still around 2.6x, and gross leverage is still above 3.3x by rough calculation.
The debt paydown materially improves the story. The filing indicates that about $746 million of proceeds will go to the term loan, and a pro forma adjustment indicates roughly $49.8 million in interest expense reduction tied to that repayment. That makes Arxis' IPO partly a valuation event and partly a refinancing event.
The first risk is governance. Arcline will retain 99.13% of voting power after the offering through Class B and convertible common stock. Public investors will own listed equity, but not control it.
The second is structure. Cornerstone investors indicated interest in up to $400 million of shares, which helps de-risk demand, but those shares are not locked up. That improves order-book optics now, yet it reduces one layer of aftermarket support later.
The third is integration discipline. Arcline has a large acquisition track record, and Arxis itself is the product of a broad consolidation strategy. That can create scale and pricing power, but it can also make quality-of-earnings analysis more demanding.
Arxis is expected to price during the week of April 13, 2026, with market calendars widely indicating April 16, 2026, as the expected Nasdaq debut date under ARXS.
The expected range is $25 to $28 per share for 37,735,849 shares of Class A common stock. That implies gross proceeds of roughly $943 million to $1.06 billion before expenses and before any overallotment.
The biggest risk is that investors pay a premium multiple before Arxis proves that its margins, pricing power, and acquisition integration can hold up as a public company.
Arxis is arriving with real scale, strong margins, proprietary product exposure, and end markets that public investors currently want. That makes Arxix IPO credible.
But credibility is not the same as cheapness. At $25 to $28 a share, Arxis is not being offered as a turnaround or a balance-sheet repair special. It is being offered as a premium aerospace and defense compounder.
The real valuation test is whether the market believes that the post-IPO company deserves that status immediately, or only after it proves it can convert sponsor-built scale into durable public-market performance.
Disclaimer: This material is for general information purposes only and is not intended as (and should not be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by EBC or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person
